Altered systemic metabolism in patients with DM is associated with hypercoagulability, endothelial dysfunction, and platelet activation, together resulting in a prothrombotic state (23) that possibly requires long-term anti-thrombotic therapy or a more potent P2Y12 inhibitor. This evidence concerns the gene P2RY12 and diabetes mellitus.